Keywords: roche, fuzeon, cost-effective, hiv, new, evaluation, presented
Roche's Fuzeon more cost-effective in HIV
Article | 03 November 2003
A new evaluation presented at the European AIDS Clinical SocietyCongress in Warsaw, Poland, at end-October shows that Fuzeon (enfuvirtide) was ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
